Isosilybin B Inhibitor

Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activity that is mediated via cell cycle arrest and apoptosis induction. Isosilybin B showed inhibitory effect on CYP2C8 activity. It inhibited both monophenolase (IC50=1.7-7.6uM) and diphenolase (IC50=12.1-44.9uM) of tyrosinase.

Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.PLoS One. 2012;7(4):e34630.
Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.PLoS One. 2012;7(4):e34630.
Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.Oncogene. 2008 Jun 26;27(28):3986-98.
Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells.Carcinogenesis. 2007 Jul;28(7):1533-42.

Small volumes of Isosilybin B, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5760532 is an inhibitor targeting Isosilybin B.